Influence of intratumoral microbiome on the occurrence and development of liver cancer

doi:10.3877/cma.j.issn.1674-1358.2025.04.001

Abstract

Abstract:

According to the National Cancer Center’s 2024 National Cancer Report, liver cancer remains the second leading cause of cancer death in our country. A large number of studies have found that microbes are widely present in various types of cancer tissues such as colorectal cancer, pancreatic cancer and breast cancer. Their composition is different from that of normal tissues. In addition, some studies have found that intratumoral microbiome has an important effect on the occurrence, development of tumors. The immune microenvironment, metabolic pathways and epigenetic modification might be the main mechanisms. In this paper, the ways that the intratumoral microbiome of liver cancer affected tumour occurrence and development, and the role in clinical treatment and prevention were reviewed.

Key words: Liver cancer, Intratumoral microbiome, Immunity, Metabolism

Yiyang Sun, Feili Wei, Wei Hou, Zhongjie Hu. Influence of intratumoral microbiome on the occurrence and development of liver cancer[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2025, 19(04): 193-196.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2025.04.001

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2025/V19/I04/193

References 40

[1]	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl),2022,135(5):584-590.
[2]	Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin,2023,73(1):17-48.
[3]	Cao M, Li H, Sun D, et al. Cancer burden of major cancers in China: A need for sustainable actions[J]. Cancer Commun (Lond), 2020,40(5):205-210.
[4]	Tilg H, Zmora N, Adolph TE, et al. The intestinal microbiota fuelling metabolic inflammation[J]. Nat Rev Immunol,2020,20(1):40-54.
[5]	Singh V, Yeoh BS, Chassaing B, et al. Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer[J]. Cell,2018,175(3):679-694. e22.
[6]	Wang D, Doestzada M, Chen L, et al. Chen characterization of gut microbial structural variations as determinants of human bile acid metabolism[J]. Cell Host Microbe,2021,29(12):1802-1814. e5.
[7]	沈华娟，庄剑波，刘春. 幽门螺杆菌感染抗体分型与胃黏膜炎性病变程度及黏膜组织学变化间的相关性[J/CD]. 中华实验和临床感染病杂志(电子版),2024,18(3):156-162.
[8]	Li WQ, Zhang JY, Ma JL, et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial[J]. BMJ,2019,366:I5016.
[9]	Hong J, Guo F, Lu SY, et al. F. nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer[J]. Gut, 2021,70(11):2123-2137.
[10]	Wang ML, Rousseau B, Qiu KY, et al. Killing tumor-associated bacteria with a liposomal antibiotic generates neoantigens that induce anti-tumor immune responses[J]. Nat Biotechnol,2024, 42(8):1263-1274.
[11]	Yang L, Li A, Wang Y, Zhang Y. Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy[J]. Signal Transduct Target Ther,2023,8(1):35.
[12]	Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy[J]. J Hepatol,2020,72(3):558-577.
[13]	Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria[J]. Science,2020,368(6494):973-980.
[14]	Tilg H, Adolph TE, Trauner M. Gut-liver axis: Pathophysiological concepts and clinical implications[J]. Cell Metab,2022, 34(11):1700-1718.
[15]	Sookoian S, Salatino A, Castaño GO, et al. Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease[J]. Gut, 2020,69(8):1483-1491.
[16]	Leinwand JC, Paul B, Chen R, et al. Intrahepatic microbes govern liver immunity by programming NKT cells[J]. J Clin Invest,2022,132(8):e151725.
[17]	Wang X, Fang Y, Liang W, et al. Gut-liver translocation of pathogen Klebsiella pneumoniae promotes hepatocellular carcinoma in mice[J]. Nat Microbiol,2025,10(1):169-184.
[18]	Song Q, Zhang X, Liu W, et al. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma[J]. J Hepatol,2023,79(6):1352-1365.
[19]	He Y, Zhang Q, Yu X, et al. Overview of microbial profiles in human hepatocellular carcinoma and adjacent nontumor tissues[J]. J Transl Med,2023,21(1):68.
[20]	Yao C, Lan D, Li X, et al. Porphyromonas gingivalis is a risk factor for the development of nonalcoholic fatty liver disease via ferroptosis[J]. Microbes Infect,2022,25(1-2):105040.
[21]	Huang JH, Wang J, Chai XQ, et al. The intratumoral bacterial metataxonomic signature of hepatocellular carcinoma[J]. Microbiol Spectr,2022,10(5):e0098322.
[22]	Chai X, Wang J, Li H, et al. Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma[J]. Gut Microbes,2023,15(1):2156255.
[23]	Li S, Xia H, Wang Z, et al. Intratumoral microbial heterogeneity affected tumor immune microenvironment and determined clinical outcome of HBV-related HCC[J]. Hepatology,2023,78(4):1079-1091.
[24]	Li J, Zhai X, Chen C, et al. The intrahepatic bacterial metataxonomic signature of patients with hepatocellular carcinoma[J]. Sci Rep,2024, 14(1):29077.
[25]	Xue C, Jia J, Gu X, et al. Intratumoral bacteria interact with metabolites and genetic alterations in hepatocellular carcinoma[J]. Signal Transduct Target Ther,2022,7(1):335.
[26]	Chen W, Wen L, Bao YY, et al. Gut flora disequilibrium promotes the initiation of liver cancer by modulating tryptophan metabolism and up-regulating SREBP2[J]. Proc Natl Acad Sci USA,2022,119(52): e2203894119.
[27]	Wang G, He X, Wang Q. Intratumoral bacteria are an important "accomplice" in tumor development and metastasis[J]. Biochim Biophys Acta Rev Cancer,2023,1878(1):188846.
[28]	Lau HC, Zhang X, Ji F, et al. Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid[J]. EBioMedicine,2024,100:104952.
[29]	Luo Z, Ji Y, Zhang D, et al. Microbial DNA enrichment promotes liver steatosis and fibrosis in the course of non-alcoholic steatohepatitis[J]. Acta Physiol (Oxf),2022,235(3):e13827.
[30]	Liu B, Zhou Z, Jin Y, et al. Hepatic stellate cell activation and senescence induced by intrahepatic microbiota disturbances drive progression of liver cirrhosis toward hepatocellular carcinoma[J]. J Immunother Cancer,2022,10(1):e003069.
[31]	Li X, Ramadori P, Pfister D, et al. The immunological and metabolic landscape in primary and metastatic liver cancer[J]. Nat Rev Cancer, 2021,21(9):541-557.
[32]	Battaglia TW, Mimpen IL, Traets JJH, et al. A pan-cancer analysis of the microbiome in metastatic cancer[J]. Cell,2024,187(9):2324-2335. e19.
[33]	Sun L, Ke X, Guan A, et al. Intratumoural microbiome can predict the prognosis of hepatocellular carcinoma after surgery[J]. Clin Transl Med,2023,13(7):e1331.
[34]	Behary J, Amorim N, Jiang XT, et al. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma[J]. Nat Commun,2021,12(1):187.
[35]	Schneider KM, Mohs A, Gui W, et al. Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment[J]. Nat Commun,2022,13(1):3964.
[36]	Byrd DA, Fan W, Greathouse KL, et al. The intratumor microbiome is associated with microsatellite instability[J]. J Natl Cancer Inst,2023, 115(8):989-993.
[37]	Fu Y, Li J, Cai W, et al. The emerging tumor microbe microenvironment: From delineation to multidisciplinary approach-based interventions[J]. Acta Pharm Sin B,2024,14(4):1560-1591.
[38]	Wang H, Rong X, Zhao G, et al. The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer[J]. Cell Metab,2022,34(4):581-594. e8.
[39]	Bender MJ, McPherson AC, Phelps CM, et al. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment[J]. Cell,2023,186(9):1846-1862. e26.
[40]	Galeano Niño JL, Wu H, LaCourse KD, et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer[J]. Nature,2022,611(7937):810-817.

Please choose a citation manager

Content to export